Global Artificial Intelligence in Oncology Market Size to Hit USD 2,145.1 Million by 2025, grow at a CAGR of 33.7%
Global Artificial Intelligence in Oncology Market Key Takeaways
According to Coherent Market Insights (CMI), the global artificial intelligence in oncology market size is expected to grow more than 7.6X, from USD 2,145.1 Mn in 2025 to USD 16,382 Mn by 2032, exhibiting a robust CAGR of 33.7%.
Based on component, software/platform segment is anticipated to account for a prominent market share of 64.2% in 2025.
North America is expected to retain its dominance, accounting for more than one-third of the global artificial intelligence in oncology market share in 2025.
Europe is projected to remain the second-leading market for AI-powered oncology companies.
As per Coherent Market Insights' new global artificial intelligence in oncology market analysis, Asia Pacific is poised to witness fastest growth throughout the assessment period.
Increasing Cancer Prevalence Spurring Market Growth
Coherent Market Insights' latest global artificial intelligence in oncology market research report highlights key factors driving market growth. One such prominent growth factor is the rising incidence of cancer.
The IARC's Global Cancer Observatory projects that annual new cancer cases will surpass 35 million by 2050. This sharp rise in cancer incidence is anticipated to drive demand for artificial intelligence in oncology.
Artificial intelligence is revolutionizing oncology by enhancing cancer detection, treatment planning, and drug discovery. Therefore, growing cancer burden is poised to play a crucial role in driving adoption of AI-based oncology solutions over the forecast period.
High Implementation Costs and Data Privacy Concerns Restraining Market Growth
The global artificial intelligence in oncology market outlook indicates strong future growth. However, high implementation costs and data security concerns are limiting market growth to some extent.
Integrating AI technologies into oncology workflows requires significant investment in hardware and software. This deters small and mid-sized healthcare companies from opting for these technologies, thereby reducing global artificial intelligence in oncology market demand.
AI systems require access to large amounts of patient data, raising concerns about cybersecurity risks as well as potential misuse. This may also negatively impact the global artificial intelligence in oncology market growth during the projection period.
Get Instant Access! Purchase Research Report and Receive a 25% Discount: https://www.coherentmarketinsights.com/insight/buy-now/6509
Technological Advancements in AI Creating New Growth Prospects for the Market
Ongoing innovations in deep learning, computer vision, and natural language processing (NLP) are significantly enhancing AI applications in image analysis, drug discovery, and prognosis prediction. Such breakthroughs are expected to unlock new revenue-generation streams for industry players.
Advanced AI technologies are being increasingly integrated with imaging modalities like MRI and PET scans. This integration enables automated detection of anomalies, enhances diagnostic accuracy, and reduces human error.
Emerging Global Artificial Intelligence in Oncology Market Trends
Rising demand for precision medicine is a key growth-shaping trend in the market. Precision oncology requires analyzing large datasets, including genomics and biomarkers. This is where AI steps in, processing huge data and enabling creation of individualized therapies.
Expanding use of artificial intelligence in radiology and pathology is expected to boost the market. AI technologies are being increasingly used for tumor detection, segmentation, and classification through radiological and histopathological images. This is due to their ability to improve speed and consistency as well as reduce diagnostic errors.
Increasing adoption of AI in drug discovery and development is positively impacting the global artificial intelligence in oncology market value. This advanced technology is revolutionizing drug discovery by rapidly analyzing large datasets to identify potential drug candidates as well as predict their efficacy and toxicity.
Growing adoption of cloud-based AI solutions is significantly contributing to the expansion of the global artificial intelligence in oncology market. These solutions are increasingly favored for their cost-efficiency, scalability, and ability to provide seamless remote access to data and tools.
Analyst's View
' The global artificial intelligence in oncology market is set for rapid expansion, owing to growing prevalence of cancer, rising adoption of precision medicine, and technological advancements in AI technologies,' said senior analyst Komal Dighe.
Current Events and Their Impact on the Global Artificial Intelligence in Oncology Market
Event
Description and Impact
FDA Clears First GenAI-Powered Diagnostic Tool for Breast Cancer Detection (2025)
Description: The U.S. FDA approved a GenAI-based diagnostic platform by PathIntel, capable of identifying breast cancer subtypes with high accuracy using real-world data.
Impact: Such approvals signal growing regulatory acceptance of generative AI in oncology.
Tempus Collaborated with Boehringer to Accelerate AI Usage in Oncology
Description: In May 2025, Tempus entered a multi-year strategic collaboration with Boehringer Ingelheim to apply its AI-driven oncology insights toward cancer‑focused therapeutic discovery and biomarker development
Impact: This will likely boost growth of the AI in oncology market.
Japan's MHLW Updates Reimbursement Guidelines for AI Diagnostics
Description: Japanese Ministry of Health, Labour and Welfare (MHLW) has approved reimbursement for certain AI-enhanced imaging diagnostics
Impact: Such initiatives will increase commercial viability and adoption of AI oncology tools in Asia-Pacific, spurring more localized R&D and product launches.
Competitor Insights
Key companies listed in the global artificial intelligence in oncology market report:
- IBM Corporation
- Intel Corporation
- Azra AI
- NVIDIA Corporation
- Siemens Healthineers AG
- GE HealthCare
- Digital Diagnostics Inc.
- ConcertAI
- PathAI
- Median Technologies
- Microsoft
- Babylon
- Zebra Medical Vision
Key Developments
In June 2025, Viz.ai launched a new strategic alliance with Novartis to accelerate timely diagnosis and deliver AI-powered precision care for cancer patients. Through this collaboration, Viz.ai will focus on developing AI-powered workflows for breast and prostate cancer.
In November 2024, PathAI unveiled PathExplore Fibrosis. This new AI-powered tool is designed to revolutionize collagen, fibrosis, and fiber quantification directly from whole-slide images.
In January 2024, PathAI launched six additional oncology indications for PathExplore, expanding the AI-driven pathology panel to cover ovarian, bladder, liver, small cell lung, lymphoma, and head & neck cancers.
Global Artificial Intelligence in Oncology Market Segmentation:
By Component
Software/Platform
Hardware
Services
By Cancer Type
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others
By Treatment Type
Chemotherapy
Radiotherapy
Immunotherapy
Others
By End User:
Hospitals & Clinics
Diagnostic Centers
Biopharmaceutical Companies
Others
By Region
North America
Latin America
Europe
Asia Pacific
Middle East
Africa About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
ThreeD Capital Inc. Announces Private Placement Financing
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. ('ThreeD' or the 'Company') (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce terms to a proposed private placement financing (the 'Private Placement'). The Private Placement will consist of the sale of up to 10,500,000 units of the Company ('Units') at a price of $0.06 per Unit, for total gross proceeds raised of $630,000. Each Unit is comprised of one common share and one common share purchase warrant (a 'Warrant'). Each whole Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.15 per common share for a period of 60 months. No commission or finders' fees are expected paid as part of the Private Placement. All securities issued and issuable in connection with the Private Placement will be subject to a four-month and a day hold period. Proceeds received from the Private Placement are intended to be used for general working capital purposes and purchase of investments. In connection with the Private Placement, certain directors of the Company (collectively the 'Insiders'), intend to purchase a total of 10,500,000 Units. Insiders' participation in the Private Placement constitutes a 'related party transaction' pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Company is relying on the exemption from the valuation and minority shareholder approval requirements under MI 61-101, as the fair market value of the Insiders' participation in the Private Placement does not exceed 25% of the market capitalization of the Company. The Private Placement remains subject to the approval of the Canadian Securities Exchange. About ThreeD Capital Inc. ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD's investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company's ecosystem. For further information: Matthew Davis, CPA Chief Financial Officer and Corporate Secretary info@ Phone: 416-941-8900 The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. Forward-Looking Statements This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Globe and Mail
8 minutes ago
- Globe and Mail
Equitable Holdings Declares Common and Preferred Stock Dividends
Equitable Holdings, Inc. (NYSE: EQH), the leading financial services holding company of Equitable, AllianceBernstein and Equitable Advisors, announced today that its Board of Directors has declared a quarterly cash dividend of $0.27 per share of common stock. The dividend on the common stock will be payable August 12, 2025, to shareholders of record at the close of business on August 5, 2025. The Company's board also declared the following cash dividends: Quarterly dividend of $328.125 per share on Series A 5.25% Non-Cumulative Perpetual Preferred Stock, with a liquidation preference of $25,000 per share, which are represented by depositary shares (NYSE: EQH PR A), each representing a 1/1,000th interest in a share of preferred stock, holders of which will receive $0.328125 per depositary share. The dividend will be payable on September 15, 2025, to holders of record as of September 4, 2025. Quarterly dividend of $268.750 per share on Series C 4.30% Non-Cumulative Perpetual Preferred Stock, with a liquidation preference of $25,000 per share, which are represented by depositary shares (NYSE: EQH PR C), each representing a 1/1,000th interest in a share of preferred stock, holders of which will receive $0.26875 per depositary share. The dividend will be payable on September 15, 2025, to holders of record as of September 4, 2025. About Equitable Holdings Equitable Holdings, Inc. (NYSE: EQH) is a leading financial services holding company comprised of complementary and well-established businesses, Equitable, AllianceBernstein and Equitable Advisors. Equitable Holdings has $1 trillion in assets under management and administration (as of 3/31/2025) and more than 5 million client relationships globally. Founded in 1859, Equitable provides retirement and protection strategies to individuals, families and small businesses. AllianceBernstein is a global investment management firm that offers diversified investment services to institutional investors, individuals and private wealth clients. Equitable Advisors, LLC (Equitable Financial Advisors in MI and TN) has 4,500 duly registered and licensed financial professionals that provide financial planning, wealth management, retirement planning, protection and risk management services to clients across the country.
Globe and Mail
8 minutes ago
- Globe and Mail
ProFrac Holding Corp. Announces Second Quarter 2025 Earnings Release and Conference Call Schedule
ProFrac Holding Corp. (NASDAQ: ACDC) ("ProFrac" or the "Company") announced today that it will report its second quarter 2025 financial results prior to the Company's conference call, which will be webcasted on Thursday, August 7, 2025, at 11:00 a.m. Eastern / 10:00 a.m. Central. To register for and access the event, please click here. An archive of the webcast will be available shortly after the call's conclusion on the IR Calendar section of ProFrac's investor relations website for 90 days. About ProFrac Holding Corp. ProFrac Holding Corp. is a technology-focused, vertically integrated and innovation-driven energy services holding company providing hydraulic fracturing, proppant production, related completion services and complementary products and services to leading upstream oil and natural gas companies engaged in the exploration and production ("E&P") of North American unconventional oil and natural gas resources. ProFrac operates through three business segments: Stimulation Services, Proppant Production and Manufacturing, in addition to Other Business Activities. For more information, please visit ProFrac's website at
